I don't keep up with trials, and drugs in the pipeline, but I was checking on the stock market today and noticed that Acorda had a HUGE gain (versus most every other stock that took a loss.)
Looking a little further, the gain was because Acorda won a couple patent challenges on Ampyra. But in looking up Acorda, I came across a trial of the MS med mentioned in the title. It's in phase I trials. Seems to be a Remyelinating med. Here's the link to the article on the med (not sure whether the mods will have to remove it or not...but if so, just google Acorda and at their website it's under Products and Research.
http://www.acorda.com/products/resea...opment/rhigm22
I see they work with Mayo, and was wondering if anyone was in the trial?
Looking a little further, the gain was because Acorda won a couple patent challenges on Ampyra. But in looking up Acorda, I came across a trial of the MS med mentioned in the title. It's in phase I trials. Seems to be a Remyelinating med. Here's the link to the article on the med (not sure whether the mods will have to remove it or not...but if so, just google Acorda and at their website it's under Products and Research.
http://www.acorda.com/products/resea...opment/rhigm22
I see they work with Mayo, and was wondering if anyone was in the trial?
Comment